Abstract 398O
Background
Intensive follow-up of patients (pts) after curative surgery for CRC is recommended by various scientific societies. These recommendations are mainly based on expert opinions and results of the few clinical trials performed are controversial. Moreover, no survival benefit has been demonstrated.
Methods
PRODIGE 131 is a prospective multicentre controlled trial evaluating by double randomisation the impact of i) intensive radiological monitoring (CT-scan/6m) versus a standard one (abdominal ultrasound/3m and thoracic radiography/6m) and ii) CEA assessment versus no, in the follow-up of resected stage II or III CRC with no evidence of residual disease on post-surgical investigation in France and Belgium. The primary endpoint was 5-year overall survival (OS).
Results
Between 09/2009 and 04/2015, 1995 pts were included (75.9%< 75 years old, 16% rectal, 44% left colon cancer (CC)). Among CC 52 % were Stage II (25% received adjuvant chemotherapy). With a median follow-up of 6.5 years, cancer recurrence was detected in 22% of the cases and second CRC in 1.7%. Among recurrences in CC, 8.4% were localized, 74.7% metastatic, and 15.7% both. These pts were treated with curative intent, respectively in 86.7%, 52.3% & 44.6%. Surgical treatment of recurrence with curative intent was 40.9% in the minimum follow-up group (No CEA & standard imaging), 66.3% in the CEA & standard imaging group, 50.7% in the No CEA & CT, and 59.5% in the maximum follow-up group (CEA & CT) (p=0.0035). Among recurrences in rectal cancer, 19.3% were localized, 65% metastatic, and 15.7% both. These pts were treated with curative intent, respectively in 50%, 53.7% & 38.5%. Surgical treatment of recurrence with curative intent was 42.9% in the minimum follow-up group, 57.9% in the CEA group & standard imaging, 55% in the No CEA & CT, and 47.8% in the maximum follow-up group (NS). None of the follow-up modalities resulted in a difference in OS (2nd interim analysis - 455 events).
Conclusions
After curative surgery, the addition of CEA and/or CT does not provide any benefit in 5-year OS, but allows more curative intent secondary surgeries for patients with a more intensive follow-up. Final results of the study will be reported at the meeting. Ref: (1) Lepage Dig Liver Dis. 2015.
Clinical trial identification
NCT00995202.
Editorial acknowledgement
Legal entity responsible for the study
FFCD.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
396O - Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
Presenter: Thierry André
Session: Proffered Paper - GI, colorectal
Resources:
Abstract
Slides
Webcast
397O - Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
Presenter: Erika Martinelli
Session: Proffered Paper - GI, colorectal
Resources:
Abstract
Slides
Webcast
399O - Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial
Presenter: Sara Lonardi
Session: Proffered Paper - GI, colorectal
Resources:
Abstract
Slides
Webcast
Invited Discussant 396O and 397O
Presenter: Chiara Cremolini
Session: Proffered Paper - GI, colorectal
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Michel Ducreux
Session: Proffered Paper - GI, colorectal
Resources:
Webcast
Invited Discussant 398O and 399O
Presenter: Timothy Price
Session: Proffered Paper - GI, colorectal
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Michel Ducreux
Session: Proffered Paper - GI, colorectal
Resources:
Webcast